After MURANO: Roche/AbbVie Map Venclexta's Expansion Past CLL
Executive Summary
Sponsors expect that if Venclexta demonstrates compelling early data in new indications – like acute myeloid leukemia and multiple myeloma – the US FDA will be willing to help speed access for patients.
You may also be interested in...
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.
Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
The latest drug development news and highlights from our US FDA Performance Tracker.